tbuckley/cabot-search huggingface dataset:
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials
Authors: Ying Yuan, Kenneth R. Hess, Susan G. Hilsenbeck, Mark R. Gilbert
Journal: Clinical Cancer Research (2016)

Despite more than two decades of publications that offer more innovative model-based designs, the classical 3 + 3 design remains the most dominant phase I trial design in practice. In this article, we introduce a new trial design, the Bayesian optimal interval (BOIN) design. The BOIN design is easy to implement in a way similar to the 3 + 3 design, but is more flexible for choosing the target toxicity rate and cohort size and yields a substantially better performance that is comparable with that of more complex model-based designs. The BOIN design contains the 3 + 3 design and the accelerated titration design as special cases, thus linking it to established phase I approaches. A numerical study shows that the BOIN design generally outperforms the 3 + 3 design and the modified toxicity probability interval (mTPI) design. The BOIN design is more likely than the 3 + 3 design to correctly select the MTD and allocate more patients to the MTD. Compared with the mTPI design, the BOIN design has a substantially lower risk of overdosing patients and generally a higher probability of correctly selecting the MTD. User-friendly software is freely available to facilitate the application of the BOIN design. Clin Cancer Res; 22(17); 4291-301. ©2016 AACR.
SURG-19CLINICAL TRANSLATION OF A NOVEL VIDEO IMAGING SYSTEM FOR NEAR-INFRARED FLUORESCENCE GUIDED RESECTION OF BRAIN TUMORS
Authors: Adam Mamelak, Pramod Butte, David Kittle, Julie Parrish-Novak, Jeff Perry, Dennis Miller, Laura Ishak, Chirag Patil, Keith Black
Journal: Neuro-Oncology (2015)
An implantable and controlled drug-release silk fibroin nanofibrous matrix to advance the treatment of solid tumour cancers
Authors: Maobin Xie, Dejun Fan, Yufeng Chen, Zheng Zhao, Xiaowen He, Gang Li, Aizheng Chen, Xiaojian Wu, Jiashen Li, Zhi Li, John A. Hunt, Yi Li, Ping Lan
Journal: Biomaterials (2016)
RETRACTED ARTICLE: MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma
Authors: Zhenyue He, Jun Yi, Xiaolong Liu, Jing Chen, Siqi Han, Li Jin, Longbang Chen, Haizhu Song
Journal: Molecular Cancer (2016)

Abstract Background Dysregulation of microRNAs (miRNAs) have been demonstrated to contribute to carcinogenesis. MiR-143-3p has been identified to function as a tumor suppressor in several tumors, but the role of miR-143-3p in esophageal squamous cell carcinoma (ESCC) has not been intensively investigated. Our aim was to evaluate the potential role of miR-143-3p in the progression of ESCC. Methods The expression levels of miR-143-3p and QKI-5 protein were measured in 80 resected ESCC tumor specimens and the clinicopathological significance of these levels determined. We also investigated the role of miR-143-3p in the regulation of QKI-5 expression in ESCC cell lines both in vivo and in vitro. Results MiR-143-3p levels were decreased in ESCC clinical samples and low expression of miR-143-3p was significantly associated with poor prognosis in ESCC patients. Ectopic expression of miR-143-3p suppressed proliferation and induced apoptosis in ESCC cells both in vivo and in vitro. Ectopic expression of miR-143-3p also reduced the metastatic potential of cells by selectively regulating epithelial–mesenchymal transition regulatory proteins. Furthermore, QKI-5 isoform was upregulated in ESCC tissues and was a direct target of miR-143-3p. Lastly, re-introduction of QKI-5 expression abrogated the inhibitory effects of miR-143-3p on ESCC cell proliferation and motility. Conclusions Our results demonstrate that miR-143-3p acts as a tumor-suppressor by targeting QKI-5 in ESCC, suggesting that miR-143-3p is a potential therapy for the treatment of ESCC.
P-155 Unresectable colorectal cancer liver metastases: retrospective review and survival analysis
Authors: L. Calera Urquizu, I. Pajares, A. Cebollero, C. Vallejo, R. Jaso, V. Alvarez, I. Trueba, V. Alija, M. Comin Ana, F. Rivera
Journal: Annals of Oncology (2016)
Irradiation of Cellular Blood Components with Cobalt 60 Is Very Efficient and Safe in the Prevention of Transfusion Associated Graft Versus Host Disease (TA-GVHD) in the Allogeneic Transplant Setting.
Authors: Amado J. Karduss, Eduardo Leon, Lina Buitrago, Luis R. Gomez, Alejo Jimenez, Pedro Reyes, Yadira Coll, Hilda De Ossa
Journal: Blood (2006)
Abstract 16470: Identification of Microrna in an Ovine Model of Heart Failure
Authors: Lee Lee Wong, Kar Sheng Lew, Qiying Chen, Miriam T. Rademaker, Leigh J. Ellmers, Christopher J. Charles, Arthur M Richards, Peipei Wang
Journal: Circulation (2014)

Introduction:  The well-established ovine rapid-pacing model of heart failure (HF) reproduces the pathophysiology of acute human HF in terms of its hemodynamic, neurohormonal and renal profile. This model offers opportunities to investigate the molecular pathology of HF. MicroRNAs appear to influence many aspects of the molecular response to HF. Little is known of the regulation of microRNAs in sheep.   Hypothesis:  Experimental ovine HF exhibits changes in microRNAs expression which reflects the concurrent derangement of hemodynamic and neurohormonal status.   Methods and results:  Serial hemodynamic and neurohormonal measurements were performed in sheep during the development of severe HF (14 days of rapid left ventricular pacing at 225 bpm) and over 25 days recovery following cessation of pacing (HF-R). Left ventricular tissue from non-pacing Control (n=5), HF (n=4) and HF-R (n=3) were collected. In HF, cardiac output was reduced by 60% compared to Control (p   Conclusion:  We have demonstrated the feasibility of assessing sheep microRNAs with existing microRNA array and qPCR. Taking this approach, we offer the first report of dysregulation of microRNAs in the rapid-pacing ovine model of HF.
Case report of carpal tunnel syndrome associated with tranylcypromine
Authors: W Harrison, J Stewart, R Lovelace, F Quitkin
Journal: American Journal of Psychiatry (1983)

A man who developed carpal tunnel syndrome while taking tranylcypromine was treated with 300 mg/day of pyridoxine, which resulted in significant improvement. The authors discuss the two major mechanisms by which monoamine oxidase inhibitors can inactivate pyridoxine.
Effects of Sulfonylurea Compounds on Hyperlipemia and Hypercholesteremia in Patients with Minimal Impairment of Glucose Tolerance
Authors: J C SHIPP, J F MUNROE
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 5079: Predictive Accuracy of Cardiopulmonary Exercise Stress Testing in Subjects With Chest Pain
Authors: Romualdo Belardinelli, Francesca Lacalaprice, Andi Mucaj, Giampaolo Littarru
Journal: Circulation (2008)

Cardiopulmonary exercise testing (CPET) is widely used to grade the severity of heart failure and to assess its prognosis. However, it is unknown whether CPET may identify coronary artery disease (CAD) or exclude it in patients with chest pain. We prospectively studied 1,265 consecutive patients (55±8 years, 156 women, 628 retired from work, 234 white collar, 244 blue collar) who were evaluated with ECG stress testing (TE) for chest pain. No one had a previous myocardial infarction or documented CAD. All patients performed an incremental CPET on an electronically-braked cycle ergometer (Ergometrics 800S) until volitional fatigue. ECG was recorded during the test. Cardiovascular risk factors were present in 65%. Criteria for a positive CPET were: flattening in VO2/work rate slope with an inflection point more than 1 minute earlier than peak exercise and a flattened slope from the inflection point to peak exercise (&lt;4 ml/min/W); the time from the inflection point to peak exercise should be similar in O2pulse. These two last criteria have been recently validated by our group in 202 patients with documented CAD ( R.Belardinelli et al, Eur Heart J , 2003 ; 24 : 1285 ). Follow-up lasted 12 months. Of 1,265 patients, 73 had a positive CPET and 1,192 had a negative CPET. Cardiac events occurred in 32 patients with a positive CPET and 10 out of 1,192 (positive predictive accuracy(PPV): 76%; negative predictive accuracy (NPV): 95%). Coronary angiography was performed in 73 patients with a positive CPET and revealed a CAD in 64. As compared with ET, sensitivity, specificity, PPV and NPV were all improved (ET: 48%,55%,33%,95%; CPET: 88%, 98%, 73%,99%, respectively). Patients with a peak VO2≥91% of predicted VO2max had no CAD in 100% of cases. In conclusion, CPET shows a predictive accuracy for CAD greater than TE in patients with chest pain. Its use should be encouraged among physicians in clinical practice.
Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis
Authors: Marlon Perera, Nathan Papa, Daniel Christidis, David Wetherell, Michael S. Hofman, Declan G. Murphy, Damien Bolton, Nathan Lawrentschuk
Journal: European Urology (2016)
Safe and effective pancreatic cancer PC chemotherapy CT as a target for tests of high dose HD vitamin C VC.
Authors: Howard Bruckner, Azriel Hirschfeld, Karen Hoffman
Journal: Journal of Clinical Oncology (2015)

e15212 Background: In vitro HD VC may improve specific drugs for specific diseases. VC is in wide clinical use and deserves further testing of feasible safety and quality of life QOL goals. PC CTs are ideal for tests due to high adverse event AE rates and the many patients pts ineligible for safe CT. GFLIO and GFLIO D were selected for testing because of the median survival MST of 15-24 mo in 6 series, 800 PC pts, and safe benefit for high risk ineligible pts (Bruckner et al, ASCO 2008, 2012). Methods: HD VC 25-100 grams, 2 times per wk was added to CT which included GFLIO and GFLIO D. Eligible pts had worsening advanced solid tumors; CT failed or untreated; Performance Status PS 1 or outpt 2; poor tolerance to CT or refused CT because of AE concerns. CT continued until no benefit; worse disease, QOL or limiting AE. Data included CBC CMP urine and AE QOL, dedicated forms weekly (CTCAE v 4.03). An initial VC tolerance test (G6PD glucose 6 phosphate dehydrogenase). GCSF was minimally used, only as needed, and titrated down to 2, 300 mcg doses. Safeguards included Helsinki consent, IRB, outside monitors and intent to treat analysis. Results: Pts, 35, 18 GI, 9 GYN had baseline AEs symptoms Sxs, Median 4, Range 1-8 per pt. With 6 wks or more of CT and VC (no exclusions, no drop outs) there were no AEs complications discontinuations of CT, hospitalizations, grade IV (and few grade IIIs). AEs-Sxs improved for 21, stable for 12 and worse for 2 pts (1 worse due to disease (progression 11). Common AEs-Sxs - gr1, few gr2- many present from baseline were; anemia, 29, hypertension 27, GI 24, abnormal liver function 23, fatigue 22, pain 17, platelets 10. There was a conspicuous absence of withdrawals, weight loss, nutritional failure, poor diabetes control and thromboembolism. Conclusions: VC with cumulative GFLIO CT produced near absence of complicated, limiting or expected worsening of AEs -Sxs. VC modulation is testworthy especially for those pts now deemed ineligible due to age, PS or poor tolerance to CT. Pts may also have had antitumor benefit after they failed the same CT. Thus both safety! Individual common AEs-Sxs cited above and efficacy drug interaction deserves prospective attention.US IND # 119,005, supported by The Marcus Foundation.
Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): Safety, efficacy, and updated translational results.
Authors: Cindy Neuzillet, Jean-François Seitz, Laetitia Fartoux, David Malka, Gérard Lledo, Annemilai Tijeras-Raballand, Armand De Gramont, Maxime Ronot, Mohamed Bouattour, Chantal Dreyer, Alexandre Amin, Philippe Brunisholz - Bourget, Alexandra Hadengue, Nelly Roldan, Benoist Chibaudel, Eric Raymond, Sandrine J. Faivre
Journal: Journal of Clinical Oncology (2015)

343 Background: There is no validated option beyond gemcitabine plus platinum standard first-line combination for advanced cholangiocarcinoma (CK). Second-line 5FU-based chemotherapy yields a median progression-free survival (PFS) and overall survival (OS) of 3 and 6-7 months, respectively. Intrahepatic CK subtypes overexpress VEGF, providing a rationale for testing sunitinib as second-line treatment in patients (pts) with advanced intrahepatic CK. Methods: A multicenter phase 2 study was designed for pts with locally advanced or metastatic intrahepatic CK after failure of first-line gemcitabine-based chemotherapy. Sunitinib was given at the dose of 37.5 mg/day continuously until disease progression or limiting toxicity. Pts were required to be ECOG PS 0-1 and with adequate liver function (alkaline phosphatase and transaminases &lt; 5ULN, bilirubin &lt;1.5ULN). Main objective was to exceed a median OS of 6.3 months. Secondary endpoints were PFS, response (RECIST 1.1 &amp; Choi criteria), safety, pharmacokinetics (PK) and biomarker analysis (VEGFA, VEGFC, sKIT, HGF, SDF1, and osteopontin). Results: 53 pts were enrolled, with 34 pts evaluable for intermediate safety and efficacy analysis. Median age was 62 years (range 36–80), with 19 females/15 males. ECOG PS was 0/1 in 23/11 pts. Sixteen pts had prior surgical resection and 8 pts received adjuvant chemotherapy. Five pts (15%) had partial responses and 24 stable diseases (71%) by RECIST (disease control rate 85%). Ten pts had disease control &gt; 6 months (range 6-14 months). With a median follow-up of 15.4 months, median OS was 9.6 months [95%CI: 5.8-13.1]. Median PFS was 5.2 months. Frequent adverse events were grade (Gr) 1-2 asthenia (80% of pts), mucositis (80%), diarrhea (60%), and hand-foot syndrome (43%). Gr 3/4 asymptomatic hematological toxicity occurred in 25% of pts (neutropenia n=8, thrombocytopenia n=7), Gr 3 hypertension was observed in 7 pts, and Gr 3 asthenia in 4 pts. Updated PK and biomarker analysis will be presented at the meeting. Conclusions: Second line sunitinib is well tolerated and shows promising activity with a 9.6-month OS in pts with advanced intrahepatic CK. Clinical trial information: NCT01718327.
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Authors: Lorenzo Guglielmetti, Damien Le Dû, Nicolas Veziris, Eric Caumes, Dhiba Marigot-Outtandy, Yazdan Yazdanpanah, Jérôme Robert, Mathilde Fréchet-Jachym
Journal: European Respiratory Journal (2016)

Bedaquiline (Bdq) is approved for the treatment of multidrug-resistant (MDR) tuberculosis (TB). In a phase IIb trial, Bdq allowed a significant reduction in time to culture conversion and improved outcome in MDR-TB patients [1, 2]. Preliminary reports of Bdq compassionate use have shown promising results [3–5]. However, in an early bactericidal activity (EBA) study, the association of moxifloxacin (Mfx) with PA-824 and pyrazinamide showed better activity than Bdq-based associations [6]. In addition, resistance to fluoroquinolones (Fq) has been associated with poorer outcome in MDR-TB before Bdq use [7]. These data reinforce the pivotal role of Fq. Comparing Bdq to Fq in interventional studies is challenging. Indeed, the paucity of drugs available for MDR-TB treatment, and the need for combination therapy, often impose the need to use all available drugs. Bedaquiline and fluoroquinolone treatments give similar culture conversion rates at 6 months in MDR-TB patients <http://ow.ly/oqVY300mJCy> The members of the MDR-TB Management Group of the French National Reference Center for Mycobacteria (Paris) are as follows: C. Andrejak, A. Aubry, C. Bernard, F. Brossier, K. Chadelat, B. Dautzenberg, B. Henry, V. Jarlier, M. Jaspard, L. Raskine and B. Rivoire. The members of the Physicians of the French MDR-TB Cohort are as follows: N. Amiot (Orleans), E. Aslangul (Paris-Hôtel Dieu), P. Assouline (Longjumeau), E. Bergot (Caen), J.F. Boitier (Lagny), A. Bourgarit (Paris-Saint-Louis), A.S. Carrie (Avicenne), M. Caseris (Paris-Bichat), L. Colombain (Perpignan), H. Cordel (Saint Denis), N. De Castro (Paris-Lariboisière), C. Delanoe (Paris-Bichat), V. Delcey (Paris-Lariboisière), M. De Menthon (Paris-Saint-Louis), R. De Meyer-Cristiani (Bastia), B. Duchemann (Avicenne), J. Dumoulin (Boulogne-Billancourt), C. Duval (Juvisy-sur-Orge), L.I. Escaut (Paris-Kremlin Bicêtre), H. Ferrand (Paris-Bichat), R. Flicoteaux (Paris-Bichat), P. Fraisse (Strasbourg), S. Gallien (Paris-Saint-Louis), S. Girard (Le Mans), C. Godet (Poitiers), M. Gousseff (Avicenne), D. Herman (Nevers), S. Jaureguiberry (Paris-Pitié-Salpêtrière), V. Joly (Paris-Bichat), J. Le Grusse (Toulouse), N. Lerolle (Paris-Saint-Louis), E. Leroy-Terquem (Meulan), D. Liné (Soissons), A. Lopes (Paris-Lariboisière), J. Macey (Paris-Cochin), G. Mellon (Paris-Bichat), J.L. Meynard (Paris-Saint-Antoine), J.C. Mouries (Bastia), J.M. Naccache (Paris-Tenon), E. Ngwem (Créteil), G. Oliviero (Longjumeau), B. Philippe (Pontoise), C. Richaud (Paris-Necker), C. Rioux (Paris-Bichat), Z. Saakashvili (Créteil), T.A. Szwebel (Paris-Hôtel Dieu) and P. Vaillant (Nancy). The authors thank all physicians and microbiologists who provided data for the study.
Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals
Authors: Mohammed K. Ali, Kavita Singh, Dimple Kondal, Raji Devarajan, Shivani A. Patel, Roopa Shivashankar, Vamadevan S. Ajay, A.G. Unnikrishnan, V. Usha Menon, Premlata K. Varthakavi, Vijay Viswanathan, Mala Dharmalingam, Ganapati Bantwal, Rakesh Kumar Sahay, Muhammad Qamar Masood, Rajesh Khadgawat, Ankush Desai, Bipin Sethi, Dorairaj Prabhakaran, K.M. Venkat Narayan, Nikhil Tandon
Journal: Annals of Internal Medicine (2016)

Achievement of diabetes care goals is suboptimal globally. Diabetes-focused quality improvement (QI) is effective but remains untested in South Asia.
Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
Authors: Evans Trj., E Wylie, J C Garcia, F Coxon, L Wall, M Eatock, T Maughan, M Highley, P B Zimmerli
Journal: Annals of Oncology (2006)
Endoscopic clip closure of a duodenocolic fistula secondary to a migrated biliary stent
Authors: Ramon Sanchez-Ocaña, Carlos Chavarria-Herbozo, Andrés Figueroa Marrero, Maria-Teresa Herranz Bachiller, Irene Peñas-Herrero, Carlos de la Serna-Higuera, Manuel Perez-Miranda
Journal: Endoscopy (2016)

A 72-year-old man presented with acute cholangitis. He underwent endoscopic retrograde cholangiography (ERCP), which revealed a type IIIb Klatskin tumor. An 8.5-Fr, 12-cm plastic biliary stent was placed. Cholangiocarcinoma was confirmed cytologically and this was deemed unresectable.
Incidental Warthin Tumor on Pertechnetate Scintigraphy
Authors: Mukta Kulkarni, Shubhangi Shetkar, Prathamesh Joshi, Sanket Kasaliwal, Shrikant Chaudhari
Journal: Clinical Nuclear Medicine (2016)

A 30-year-old woman underwent 99mTc-pertechnetate scintigraphy for evaluation of thyrotoxicosis. The scintigraphy revealed hypervascular thyroid gland with markedly increased trapping function in both the lobes suggesting diagnosis of Graves disease. Incidentally, a hypervascular and pertechnetate avid focus was seen along the lateral margin of the right parotid gland. Pertechnetate avidity and site of uptake suggested possibility of Warthin tumor. Clinical examination and ultrasonography revealed a well-defined lesion in the superficial lobe of the right parotid gland favoring diagnosis of benign lesion. Postsurgery specimen confirmed diagnosis of Warthin tumor.
The value of sound waves and pleural manometry in diagnosing a pleural effusion with the dual diagnosis
Authors: Amit Chopra, Rahul Argula, Christopher Schaefer, Marc A Judson, Terrill Huggins
Journal: Thorax (2016)

An 83-year-old woman presented with a recurrent, right-sided pleural effusion. She had undergone three large volume thoracentesis in the past 2 years, which revealed a ‘clear appearing’ transudative effusion. She had a remote history of haemothorax, a complication from dual chamber pacemaker placement. A chest radiograph (figure 1A) showed a moderate sized, right pleural effusion. Pleural ultrasonography revealed an anechoic fluid collection. Approximately 1.2 L of yellow fluid was removed during thoracentesis. Pleural manometry performed during the thoracentesis revealed a biphasic pressure-volume (P-V) curve showing a steep increase in pleural space elastance at the terminal stages of drainage suggesting an unexpandable lung (figure 2). An air-contrast chest CT scan (figure 1B) showed abnormal visceral pleural thickening consistent with a …
Johnson &amp; Johnson is ordered to pay $70m to boy who developed gynecomastia
Authors: Owen Dyer
Journal: BMJ (2016)

Johnson & Johnson’s Janssen Pharmaceuticals division has been ordered by a Pennsylvania court to pay $70m (£54m; €63m) in damages to a young man who developed size 46DD breasts after taking the company’s antipsychotic drug risperidone (which it markets as Risperdal). Andrew Yount, 18, of Tennessee, began taking the drug when he was 5 years old, though it was not approved for use in children.

The jury found that Johnson & Johnson knew that the drug carried a risk of gynecomastia in men and boys but had “intentionally falsified, destroyed, or concealed records” to hide …